AU2012310259C1 - Dosage regime for apolipoprotein formulations - Google Patents

Dosage regime for apolipoprotein formulations Download PDF

Info

Publication number
AU2012310259C1
AU2012310259C1 AU2012310259A AU2012310259A AU2012310259C1 AU 2012310259 C1 AU2012310259 C1 AU 2012310259C1 AU 2012310259 A AU2012310259 A AU 2012310259A AU 2012310259 A AU2012310259 A AU 2012310259A AU 2012310259 C1 AU2012310259 C1 AU 2012310259C1
Authority
AU
Australia
Prior art keywords
apolipoprotein
formulation
fixed dosage
dosage
fixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012310259A
Other languages
English (en)
Other versions
AU2012310259B2 (en
AU2012310259A1 (en
Inventor
Craig RAYNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905368A external-priority patent/AU2011905368A0/en
Application filed by CSL Ltd filed Critical CSL Ltd
Priority to AU2012310259A priority Critical patent/AU2012310259C1/en
Publication of AU2012310259A1 publication Critical patent/AU2012310259A1/en
Publication of AU2012310259B2 publication Critical patent/AU2012310259B2/en
Application granted granted Critical
Publication of AU2012310259C1 publication Critical patent/AU2012310259C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012310259A 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations Active AU2012310259C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012310259A AU2012310259C1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2011905368 2011-12-21
AU2011905368A AU2011905368A0 (en) 2011-12-21 Dosing regime for apolipoprotein formulations
PCT/AU2012/001345 WO2013090978A1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations
AU2012310259A AU2012310259C1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Publications (3)

Publication Number Publication Date
AU2012310259A1 AU2012310259A1 (en) 2013-07-11
AU2012310259B2 AU2012310259B2 (en) 2015-07-30
AU2012310259C1 true AU2012310259C1 (en) 2016-07-14

Family

ID=48667485

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012310259A Active AU2012310259C1 (en) 2011-12-21 2012-11-02 Dosage regime for apolipoprotein formulations

Country Status (16)

Country Link
US (3) US20140378376A1 (cg-RX-API-DMAC10.html)
EP (1) EP2793913B1 (cg-RX-API-DMAC10.html)
JP (2) JP6144276B2 (cg-RX-API-DMAC10.html)
KR (3) KR20140107536A (cg-RX-API-DMAC10.html)
CN (2) CN104010646A (cg-RX-API-DMAC10.html)
AU (1) AU2012310259C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014014403A8 (cg-RX-API-DMAC10.html)
CA (1) CA2857968A1 (cg-RX-API-DMAC10.html)
DK (1) DK2793913T3 (cg-RX-API-DMAC10.html)
ES (1) ES2955110T3 (cg-RX-API-DMAC10.html)
IL (1) IL233236A0 (cg-RX-API-DMAC10.html)
MX (1) MX377093B (cg-RX-API-DMAC10.html)
PL (1) PL2793913T3 (cg-RX-API-DMAC10.html)
RU (1) RU2014129505A (cg-RX-API-DMAC10.html)
SG (1) SG11201402556RA (cg-RX-API-DMAC10.html)
WO (1) WO2013090978A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9645037B2 (en) 2011-09-28 2017-05-09 Hunter Engineering Company Method and apparatus for wheel assembly lateral force measurement
CN104010646A (zh) * 2011-12-21 2014-08-27 Csl有限公司 用于载脂蛋白制剂的剂量方案
KR20240044543A (ko) 2016-11-10 2024-04-04 시에스엘 리미티드 심근경색의 재구성된 고밀도 지질단백질 치료

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
WO2002038609A2 (en) * 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
MXPA04011312A (es) * 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
US6953840B2 (en) * 2002-07-30 2005-10-11 Esperion Therapeutics, Inc. Methods of using non-human animal Apolipoprotein A-I protein
AP2006003578A0 (en) * 2003-10-20 2006-04-30 Esperion Therapeutics Inc Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes.
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
BRPI0614966A2 (pt) * 2005-08-26 2016-09-13 Cerenis Therapeutics Holding S A vetor de expressão, bactéria de ácido lático, apolipoproteína isenta de endotoxina, e, método de produção de uma apolipoproteína isenta de endotoxina
US20090297577A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of Apolipoproteins and Their Derivatives
CN104010646A (zh) * 2011-12-21 2014-08-27 Csl有限公司 用于载脂蛋白制剂的剂量方案

Also Published As

Publication number Publication date
US20140378376A1 (en) 2014-12-25
KR20200037879A (ko) 2020-04-09
MX377093B (es) 2025-03-07
NZ624558A (en) 2015-08-28
CN104010646A (zh) 2014-08-27
BR112014014403A8 (pt) 2021-03-09
CA2857968A1 (en) 2013-06-27
AU2012310259B2 (en) 2015-07-30
ES2955110T3 (es) 2023-11-28
PL2793913T3 (pl) 2023-11-06
AU2012310259A1 (en) 2013-07-11
US20160175392A1 (en) 2016-06-23
EP2793913A1 (en) 2014-10-29
HK1199813A1 (en) 2015-07-24
RU2017129700A (ru) 2019-02-04
MX2014006589A (es) 2014-10-17
RU2017129700A3 (cg-RX-API-DMAC10.html) 2021-02-26
KR102766038B1 (ko) 2025-02-12
KR20190084334A (ko) 2019-07-16
JP6144276B2 (ja) 2017-06-07
BR112014014403A2 (pt) 2017-06-13
CN113398245A (zh) 2021-09-17
EP2793913A4 (en) 2015-06-10
KR20140107536A (ko) 2014-09-04
DK2793913T3 (da) 2023-08-21
JP2015500840A (ja) 2015-01-08
RU2014129505A (ru) 2016-02-10
US20240216467A1 (en) 2024-07-04
IL233236A0 (en) 2014-08-31
JP2017128586A (ja) 2017-07-27
WO2013090978A1 (en) 2013-06-27
SG11201402556RA (en) 2014-10-30
EP2793913B1 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
US20240216467A1 (en) Dosage regime for apolipoprotein formulations
AU2011274238B2 (en) A reconstituted high density lipoprotein formulation and production method thereof
US11957731B2 (en) Reconstituted HDL formulation
CA2486127C (en) Method of treating dyslipidemic disorders
RU2776110C2 (ru) Схема дозирования для составов аполипопротеина
HK1199813B (en) Dosage regime for apolipoprotein formulations
NZ624558B2 (en) Dosage regime for apolipoprotein formulations
DK2916857T3 (en) RECONSTITUTED HDL FORMULATION
HK1212599B (en) Reconstituted hdl formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2016